Replimune Group (NASDAQ:REPL) Shares Up 6.4% – Still a Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) were up 6.4% during mid-day trading on Wednesday . The company traded as high as $12.07 and last traded at $12.17. Approximately 66,165 shares traded hands during trading, a decline of 92% from the average daily volume of 864,305 shares. The stock had previously closed at $11.44.

Analyst Ratings Changes

A number of analysts recently weighed in on REPL shares. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright increased their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $19.43.

Replimune Group Price Performance

The business’s fifty day simple moving average is $12.70 and its 200 day simple moving average is $12.09. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The stock has a market cap of $937.66 million, a price-to-earnings ratio of -3.96 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. Charles Schwab Investment Management Inc. increased its stake in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares in the last quarter. Geode Capital Management LLC boosted its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the period. Barclays PLC grew its position in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after purchasing an additional 98,791 shares in the last quarter. LMR Partners LLP raised its stake in Replimune Group by 145.8% during the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after purchasing an additional 48,920 shares during the period. Finally, State Street Corp raised its stake in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.